Xenon Pharmaceuticals Reports Director Changes and Compensation Updates
Ticker: XENE · Form: 8-K · Filed: Apr 19, 2024 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
Xenon Pharma shakes up board, updates exec pay.
AI Summary
Xenon Pharmaceuticals Inc. announced on April 15, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of a director and the election of new directors, alongside updates to compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and compensation adjustments, which are typical for public companies and do not indicate immediate operational or financial distress.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- April 15, 2024 (date) — Date of earliest event reported
FAQ
Who departed from Xenon Pharmaceuticals Inc.'s board of directors?
The filing indicates the departure of a director, but does not name the individual in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on April 15, 2024.
What are the main items covered in this 8-K filing?
This filing covers the departure of directors, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is Xenon Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 200-3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8.
What is Xenon Pharmaceuticals Inc.'s telephone number?
The company's telephone number, including area code, is (604) 484-3300.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-04-19 16:21:11
Filing Documents
- xene-20240415.htm (8-K) — 41KB
- 0000950170-24-046023.txt ( ) — 158KB
- xene-20240415.xsd (EX-101.SCH) — 30KB
- xene-20240415_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers (b) On April 15, 2024, Dr. Simon Pimstone, chair of the board of directors (the "Board") of Xenon Pharmaceuticals Inc. (the "Company"), and Dr. Mohammad Azab, a member of the Board, each informed the Company of their respective decisions not to stand for re-election to the Board at the Company's 2024 annual meeting of shareholders (the "AGM"). Each director will continue to serve on the Board until the AGM. The decisions of Dr. Pimstone and Dr. Azab not to stand for re-election were not due to any disagreement between either director and the Company regarding its operations, policies or practices.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENON PHARMACEUTICALS INC. Date: April 19, 2024 By: /s/ Sherry Aulin Sherry Aulin Chief Financial Officer